Conference abstract · 2 Nov 2017
Conference abstractPublished 2 Nov 2017
Bio-fabrication and evaluation of alginate chitosan microcapsules of Insulin secreting β TC-6 cells in the treatment of Type 1 diabetes mellitus
Mercer University, USA; Charles River Laboratories, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Type 1 diabetes mellitus (T1DM) is a disease, characterized by lack of pancreatic islet function. Whole tissue transplantation appears to be viable alternative in the management of T1DM due to limitation of exogenous insulin therapy. This study aims at fabrication and evaluation of alginate-chitosan microcapsule encapsulated insulin secreting Ã?² TC-6 cells using specialized spraying nozzle. Microcapsules encapsulated with Ã?² TC-6 cells were fabricated using novel spraying device producing uniform spherical microcapsules. Microcapsules were characterized for permeability using molecular weight markers, stability, and cell viability using live dead staining kit. Microencapsulated Ã?² TC-6 cells were transplanted intra-peritoneally in streptozotocin (STZ) induced diabetic mice and monitored for decrease in blood glucose level and immune acceptance. Spherical microcapsules with diameter in the range of 250-350 Ã?µm were prepared at an air flow rate of 250 L/hr. Microencapsulated Ã?² TC-6 cells in alginate capsules demonstrated prolonged viability. Mice in microencapsulated cells group received microencapsulated Ã?² TC-6 cells maintains normoglycemia for 35Ã?±5 days before rejection. However, mice in unencapsulated cells group received naked Ã?² TC-6 cells rejected graft within 1 or 2 days and exhibit both cellular and humoral immune responses. CD4 T-cells mediated Th2 response i.e. humoral response was predominant in microencapsulated Ã?² TC-6 cells group and that was further confirmed from elevated levels of CD45R. Microcapsules produced by specialized nozzle were reproducible with narrow size distribution and in addition provides flexibility in producing different sized capsules. Our findings for in-vivo study revealed that transplantation of microencapsulated Ã?² TC-6 cells may be a viable alternative in the management of T1DM with greater immune acceptance.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 9 Nov 2018
Bio fabrication of smart microcapsules containing insulin secreting pancreatic islet cells: Potential applications in diabetes mellitus
Conference abstract
Bio fabrication of smart microcapsules containing insulin secreting pancreatic islet cells: Potential applications in diabetes mellitus
Perspective · 3 Feb 2023
Complications of Insulin-Producing Cells in Diabetes Mellitus Type 1
Short communication · 27 Feb 2021
Correlation between Serum 25-Hydroxyvitamin D3 and Abnormal Insulin Secretion in Patients with Type 2 Diabetes Mellitus
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Amit Bansal”
- BylineArticles whose byline prints “Sucheta D’Sa”
- BylineArticles whose byline prints “Martin J D’Souza”

